oleoylethanolamide

Oleoylethanolamide (N-Oleoylethanolamide) is a high affinity endogenous agonist of PPAR-α.

Oleoylethanolamide-D4 is the deuterated form of Oleoylethanolamide (TMSM-1810). This compound serves as a high-affinity endogenous PPAR-α agonist and is utilized in research related to obesity and atherosclerosis.

Oleoylethanolamide-D2 is the deuterated form of Oleoylethanolamide (TMSM-1810). It serves as a high-affinity endogenous PPAR-α agonist and is useful in research related to obesity and atherosclerosis.

Oleoylethanolamide-D4 (Standard) is a reference standard of Oleoylethanolamide-D4 intended for quantitative analysis, quality control, and related biochemical research applications. Oleoylethanolamide-d4 is the deuterated form of Oleoylethanolamide. This compound serves as a high-affinity endogenous PPAR-α agonist and is utilized in research related to obesity and atherosclerosis.

Oleoylethanolamide (Standard) is the standard substance of Oleoylethanolamide, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Oleoylethanolamide (N-Oleoylethanolamide) is a high affinity endogenous agonist of PPAR-α.

AM-3102 is an OEA analog that stimulates PPARα transcriptional activity and prolongs feeding latency. It is resistant to enzymatic hydrolysis and is as potent as OEA in enhancing transcriptional activity of PPARα and reducing food intake in free-feeding r

Palmitoleoyl Ethanolamide (POEA) is an endogenous fatty acid ethanolamide (FAE) and a member of the endocannabinoid-like family of molecules. It is a derivative of the monounsaturated fatty acid palmitoleic acid. Similar to the well-studied palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), POEA is thought to exert biological effects by modulating peroxisome proliferator-activated receptor α (PPAR-α), G protein-coupled receptors (e.g., GPR119), or through the "entourage effect" by modulating endocannabinoid signaling. It has demonstrated potential activities in anti-inflammation, analgesia, and metabolic regulation.

Linoleoyl Ethanolamide is an endocannabinoid agent. It acts by binding to TRPV1 increasing ERK phosphorylation and AP-1 dependent transcription in CB-receptor in an independent manner.

Linoleoyl ethanolamide phosphate is an intermediate in the biosynthesis of linoleoyl ethanolamide, generated through phospholipase C-mediated hydrolysis of N-acylphosphatidylethanolamine. Linoleoyl ethanolamide phosphate, along with other endogenous N-acylethanolamines, is thought to regulate food intake by selectively prolonging feeding latency and post-meal interval [Linoleoyl Ethanolamide Phosphate].

N-Oleoyl-DPPE ammonium is an N-acylphosphatidylethanolamine (NAPE). It serves as a biosynthetic precursor to oleoylethanolamide (OEA), an endogenous cannabinoid derivative and a peroxisome proliferator-activated receptor alpha (PPARα) agonist. N-Oleoyl-DPPE ammonium is utilized in research related to neuroinflammation and alcohol abuse.

PSN 375963 hydrochloride, a potent GPR119 agonist, demonstrates EC50 values of 8.4 μM and 7.9 μM for human and mouse GPR119, respectively. Its efficacy is comparable to that of the endogenous agonist oleoylethanolamide (OEA) [1] [2].

Elaidyl-sulfamide is a sulfamoyl analogue of oleoylethanolamide (OEA). ES is a lipid mediator of satiety that acts through the PPARα.

NAAA-IN-2 (Compound 9), a potent and selective inhibitor of NAAA, exhibits an IC50 of 50 nM. NAAA, a cysteine amidase, primarily breaks down the endogenous biolipids palmitoylethanolamide (PEA) and oleoylethanolamide (OEA). This compound demonstrates promise for inflammation and pain research [1].

NAAA-IN-3 (Compound 17a) is a potent and selective NAAA inhibitor with an IC50 of 50 nM. NAAA is a cysteine amidase that preferentially hydrolyzes the endogenous biolipids palmitoylethanolamide (PEA) and oleoylethanolamide (OEA). PEA is an endogenous agonist of the nuclear peroxisome proliferator-activated receptor-α (PPAR-α), a key regulator of inflammation and pain. The potential role of NAAA-IN-3 is as a therapeutic agent for the treatment of inflammation and pain.

NAAA-IN-1 (Compound 1) is a potent and selective NAAA inhibitor (IC50 = 7 nM) that can be used in inflammation and pain research. NAAA, a cysteine amidase, preferentially hydrolyzes the endogenous biolipids palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) [1].